Trial Profile
Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2015
Price :
$35
*
At a glance
- Drugs Metadoxine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Alcobra
- 16 Dec 2013 Primary endpoint 'Test-of-Variables-of-Attention' has been met.
- 15 Dec 2013 Results published in the Media Release.
- 01 Dec 2013 Status changed from active, no longer recruiting to completed.